Table of Content
1 INTRODUCTION
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.3 OVERVIEW OF GLOBAL CARCINOEMBRYONIC ANTIGEN (CEA) MARKET
1.4 CURRENCY AND PRICING
1.5 LIMITATION
1.6 MARKETS COVERED
2 MARKET SEGMENTATION
2.1 KEY TAKEAWAYS
2.2 ARRIVING AT THE GLOBAL CARCINOEMBRYONIC ANTIGEN (CEA) MARKET SIZE
2.2.1 VENDOR POSITIONING GRID
2.2.2 TECHNOLOGY LIFE LINE CURVE
2.2.3 TRIPOD DATA VALIDATION MODEL
2.2.4 MARKET GUIDE
2.2.5 MULTIVARIATE MODELLING
2.2.6 TOP TO BOTTOM ANALYSIS
2.2.7 CHALLENGE MATRIX
2.2.8 APPLICATION COVERAGE GRID
2.2.9 STANDARDS OF MEASUREMENT
2.2.10 VENDOR SHARE ANALYSIS
2.2.11 EPIDEMIOLOGY MODELING
2.2.12 DATA POINTS FROM KEY PRIMARY INTERVIEWS
2.2.13 DATA POINTS FROM KEY SECONDARY DATABASES
2.3 GLOBAL CARCINOEMBRYONIC ANTIGEN (CEA) MARKET: RESEARCH SNAPSHOT
2.4 ASSUMPTIONS
3 MARKET OVERVIEW
3.1 DRIVERS
3.2 RESTRAINTS
3.3 OPPORTUNITIES
3.4 CHALLENGES
4 EXECUTIVE SUMMARY
5 PREMIUM INSIGHTS
5.1 PESTEL ANALYSIS
5.2 PORTER’S FIVE FORCES MODEL
6 INDUSTRY INSIGHTS
6.1 MICRO AND MACRO ECONOMIC FACTORS
6.2 PENETRATION AND GROWTH PROSPECT MAPPING
6.3 KEY PRICING STRATEGIES
6.4 INTERVIEWS WITH SPECIALIST
6.5 ANALYIS AND RECOMMENDATION
7 INTELLECTUAL PROPERTY (IP) PORTFOLIO
7.1 PATENT QUALITY AND STRENGTH
7.2 PATENT FAMILIES
7.3 LICENSING AND COLLABORATIONS
7.4 COMPETITIVE LANDSCAPE
7.5 IP STRATEGY AND MANAGEMENT
7.6 OTHER
8 COST ANALYSIS BREAKDOWN
9 TECHNONLOGY ROADMAP
10 INNOVATION TRACKER AND STRATEGIC ANALYSIS
10.1 MAJOR DEALS AND STRATEGIC ALLIANCES ANALYSIS
10.1.1 JOINT VENTURES
10.1.2 MERGERS AND ACQUISITIONS
10.1.3 LICENSING AND PARTNERSHIP
10.1.4 TECHNOLOGY COLLABORATIONS
10.1.5 STRATEGIC DIVESTMENTS
10.2 NUMBER OF PRODUCTS IN DEVELOPMENT
10.3 STAGE OF DEVELOPMENT
10.4 TIMELINES AND MILESTONES
10.5 INNOVATION STRATEGIES AND METHODOLOGIES
10.6 RISK ASSESSMENT AND MITIGATION
10.7 FUTURE OUTLOOK
11 REGULATORY COMPLIANCE
11.1 REGULATORY AUTHORITIES
11.2 REGULATORY CLASSIFICATIONS
11.2.1 CLASS I
11.2.2 CLASS II
11.2.3 CLASS III
11.3 REGULATORY SUBMISSIONS
11.4 INTERNATIONAL HARMONIZATION
11.5 COMPLIANCE AND QUALITY MANAGEMENT SYSTEMS
11.6 REGULATORY CHALLENGES AND STRATEGIES
12 REIMBURSEMENT FRAMEWORK
13 OPPUTUNITY MAP ANALYSIS
14 VALUE CHAIN ANALYSIS
15 HEALTHCARE ECONOMY
15.1 HEALTHCARE EXPENDITURE
15.2 CAPITAL EXPENDITURE
15.3 CAPEX TRENDS
15.4 CAPEX ALLOCATION
15.5 FUNDING SOURCES
15.6 INDUSTRY BENCHMARKS
15.7 GDP RATION IN OVERALL GDP
15.8 HEALTHCARE SYSTEM STRUCTURE
15.9 GOVERNMENT POLICIES
15.1 ECONOMIC DEVELOPMENT
16 GLOBAL CARCINOEMBRYONIC ANTIGEN (CEA) MARKET, BY TEST TYPE
16.1 OVERVIEW
16.2 MOLECULAR TESTS
16.2.1 RADIOIMMUNOASSAY
16.2.2 IMMUNOHISTOCHEMISTRY
16.2.3 ELECTROCHEMILUMINESCENCE IMMUNOASSAY
16.2.4 ENZYME-LINKED IMMUNOSORBENT ASSAY (ELISA)
16.2.5 OTHERS
16.3 SEROLOGY TESTS
16.3.1 BLOOD TEST
16.3.2 ABDOMINAL WALL (PERITONEAL FLUID)
16.3.3 SPINAL CORD (CEREBROSPINAL FLUID OR CSF)
16.3.4 CHEST (PLEURAL FLUID)
16.3.5 OTHERS
16.4 OTHERS
17 GLOBAL CARCINOEMBRYONIC ANTIGEN (CEA) MARKET, BY PRODUCT TYPE
17.1 OVERVIEW
17.2 CD66A
17.3 CD66B
17.4 CD66C
17.5 CD66D
17.6 CD66E
17.7 CD66F
18 GLOBAL CARCINOEMBRYONIC ANTIGEN (CEA) MARKET, BY KIT/PACK SIZE
18.1 OVERVIEW
18.2 100 TEST
18.3 200 TEST
18.4 OTHERS
19 GLOBAL CARCINOEMBRYONIC ANTIGEN (CEA) MARKET, BY GENDER
19.1 OVERVIEW
19.2 MALE
19.2.1 GASTROINTESTINAL CANCER
19.2.2 COLORECTAL CANCER
19.2.3 PANCREATIC CANCER
19.2.4 LUNG CANCER
19.2.5 THYROID CANCER
19.2.6 OTHERS
19.3 FEMALE
19.3.1 GASTROINTESTINAL CANCER
19.3.2 COLORECTAL CANCER
19.3.3 PANCREATIC CANCER
19.3.4 BREAST CANCER
19.3.5 LUNG CANCER
19.3.6 THYROID CANCER
19.3.7 OVARIAN CANCER
19.3.8 OTHERS
20 GLOBAL CARCINOEMBRYONIC ANTIGEN (CEA) MARKET, BY AGE GROUP
20.1 OVERVIEW
20.2 ADULT
20.2.1 MOLECULAR TESTS
20.2.2 SEROLOGY TEST
20.3 GERIATRIC
20.3.1 MOLECULAR TESTS
20.3.2 SEROLOGY TEST
21 GLOBAL CARCINOEMBRYONIC ANTIGEN (CEA) MARKET, BY APPLICATION
21.1 OVERVIEW
21.2 DIAGNOSTICS
21.2.1 GASTROINTESTINAL CANCER
21.2.2 COLORECTAL CANCER
21.2.3 PANCREATIC CANCER
21.2.4 BREAST CANCER
21.2.5 LUNG CANCER
21.2.6 THYROID CANCER
21.2.7 OVARIAN CANCER
21.3 RESEARCH
21.4 OTHERS
22 GLOBAL CARCINOEMBRYONIC ANTIGEN (CEA) MARKET, BY END USER
22.1 OVERVIEW
22.2 HOSPITAL
22.2.1 BY TYPE
22.2.1.1. PRIVATE
22.2.1.2. GOVERNMENT
22.2.2 BY TIER
22.2.2.1. TIER 1
22.2.2.2. TIER 2
22.2.2.3. TIER 3
22.3 SPECIALTY CLINICS
22.4 DIAGNOSTIC CENTERS
22.5 RESEARCH AND ACADEMIC INSTITUTES
22.6 OTHERS
23 GLOBAL CARCINOEMBRYONIC ANTIGEN (CEA) MARKET, BY DISTRIBUTION CHANNEL
23.1 OVERVIEW
23.2 DIRECT TENDER
23.3 REATIL SALES
23.4 OTHERS
24 GLOBAL CARCINOEMBRYONIC ANTIGEN (CEA) MARKET, COMPANY LANDSCAPE
24.1 COMPANY SHARE ANALYSIS: GLOBAL
24.2 COMPANY SHARE ANALYSIS: EUROPE
24.3 COMPANY SHARE ANALYSIS: NORTH AMERICA
24.4 COMPANY SHARE ANALYSIS: ASIA PACIFIC
24.5 COMPANY SHARE ANALYSIS: SOUTH AMERICA
24.6 MERGERS & ACQUISITIONS
24.7 NEW PRODUCT DEVELOPMENT & APPROVALS
24.8 EXPANSIONS
24.9 REGULATORY CHANGES
24.1 PARTNERSHIP AND OTHER STRATEGIC DEVELOPMENTS
25 GLOBAL CARCINOEMBRYONIC ANTIGEN (CEA) MARKET, BY GEOGRAPHY
GLOBAL CARCINOEMBRYONIC ANTIGEN (CEA) MARKET, (ALL SEGMENTATION PROVIDED ABOVE IS REPRESENTED IN THIS CHAPTER BY COUNTRY)
25.1 NORTH AMERICA
25.1.1 U.S.
25.1.2 CANADA
25.1.3 MEXICO
25.2 EUROPE
25.2.1 GERMANY
25.2.2 FRANCE
25.2.3 U.K.
25.2.4 HUNGARY
25.2.5 LITHUANIA
25.2.6 AUSTRIA
25.2.7 IRELAND
25.2.8 NORWAY
25.2.9 POLAND
25.2.10 ITALY
25.2.11 SPAIN
25.2.12 RUSSIA
25.2.13 TURKEY
25.2.14 NETHERLANDS
25.2.15 SWITZERLAND
25.2.16 REST OF EUROPE
25.3 ASIA-PACIFIC
25.3.1 JAPAN
25.3.2 CHINA
25.3.3 SOUTH KOREA
25.3.4 INDIA
25.3.5 AUSTRALIA
25.3.6 SINGAPORE
25.3.7 THAILAND
25.3.8 MALAYSIA
25.3.9 INDONESIA
25.3.10 PHILIPPINES
25.3.11 VIETNAM
25.3.12 REST OF ASIA-PACIFIC
25.4 SOUTH AMERICA
25.4.1 BRAZIL
25.4.2 ARGENTINA
25.4.3 PERU
25.4.4 REST OF SOUTH AMERICA
25.5 MIDDLE EAST AND AFRICA
25.5.1 SOUTH AFRICA
25.5.2 GLOBAL
25.5.3 UAE
25.5.4 EGYPT
25.5.5 KUWAIT
25.5.6 ISRAEL
25.5.7 REST OF MIDDLE EAST AND AFRICA
25.6 KEY PRIMARY INSIGHTS: BY MAJOR COUNTRIES
26 GLOBAL CARCINOEMBRYONIC ANTIGEN (CEA) MARKET, SWOT AND DBMR ANALYSIS
27 GLOBAL CARCINOEMBRYONIC ANTIGEN (CEA) MARKET, COMPANY PROFILE
27.1 QUEST DIAGNOSTICS INCORPORATED.
27.1.1 COMPANY OVERVIEW
27.1.2 REVENUE ANALYSIS
27.1.3 GEOGRAPHIC PRESENCE
27.1.4 PRODUCT PORTFOLIO
27.1.5 RECENT DEVELOPMENTS
27.2 F. HOFFMANN-LA ROCHE LTD
27.2.1 COMPANY OVERVIEW
27.2.2 REVENUE ANALYSIS
27.2.3 GEOGRAPHIC PRESENCE
27.2.4 PRODUCT PORTFOLIO
27.2.5 RECENT DEVELOPMENTS
27.3 WELDON BIOTECH, INC.
27.3.1 COMPANY OVERVIEW
27.3.2 REVENUE ANALYSIS
27.3.3 GEOGRAPHIC PRESENCE
27.3.4 PRODUCT PORTFOLIO
27.3.5 RECENT DEVELOPMENTS
27.4 BIOGENEX
27.4.1 COMPANY OVERVIEW
27.4.2 REVENUE ANALYSIS
27.4.3 GEOGRAPHIC PRESENCE
27.4.4 PRODUCT PORTFOLIO
27.4.5 RECENT DEVELOPMENTS
27.5 ABBOTT
27.5.1 COMPANY OVERVIEW
27.5.2 REVENUE ANALYSIS
27.5.3 GEOGRAPHIC PRESENCE
27.5.4 PRODUCT PORTFOLIO
27.5.5 RECENT DEVELOPMENTS
27.6 THERMO FISHER SCIENTIFIC INC.
27.6.1 COMPANY OVERVIEW
27.6.2 REVENUE ANALYSIS
27.6.3 GEOGRAPHIC PRESENCE
27.6.4 PRODUCT PORTFOLIO
27.6.5 RECENT DEVELOPMENTS
27.7 MEDIX BIOCHEMICA USA INC.
27.7.1 COMPANY OVERVIEW
27.7.2 REVENUE ANALYSIS
27.7.3 GEOGRAPHIC PRESENCE
27.7.4 PRODUCT PORTFOLIO
27.7.5 RECENT DEVELOPMENTS
27.8 BOSTER BIOLOGICAL TECHNOLOGY
27.8.1 COMPANY OVERVIEW
27.8.2 REVENUE ANALYSIS
27.8.3 GEOGRAPHIC PRESENCE
27.8.4 PRODUCT PORTFOLIO
27.8.5 RECENT DEVELOPMENTS
27.9 OMEGA DIAGNOSTICS LTD.
27.9.1 COMPANY OVERVIEW
27.9.2 REVENUE ANALYSIS
27.9.3 GEOGRAPHIC PRESENCE
27.9.4 PRODUCT PORTFOLIO
27.9.5 RECENT DEVELOPMENTS
27.1 MERCK KGAA
27.10.1 COMPANY OVERVIEW
27.10.2 REVENUE ANALYSIS
27.10.3 GEOGRAPHIC PRESENCE
27.10.4 PRODUCT PORTFOLIO
27.10.5 RECENT DEVELOPMENTS
27.11 CREATIVE DIAGNOSTICS
27.11.1 COMPANY OVERVIEW
27.11.2 REVENUE ANALYSIS
27.11.3 GEOGRAPHIC PRESENCE
27.11.4 PRODUCT PORTFOLIO
27.11.5 RECENT DEVELOPMENTS
27.12 LABORATORY CORPORATION OF AMERICA HOLDINGS
27.12.1 COMPANY OVERVIEW
27.12.2 REVENUE ANALYSIS
27.12.3 GEOGRAPHIC PRESENCE
27.12.4 PRODUCT PORTFOLIO
27.12.5 RECENT DEVELOPMENTS
27.13 AVIVA SYSTEMS BIOLOGY CORPORATION
27.13.1 COMPANY OVERVIEW
27.13.2 REVENUE ANALYSIS
27.13.3 GEOGRAPHIC PRESENCE
27.13.4 PRODUCT PORTFOLIO
27.13.5 RECENT DEVELOPMENTS
27.14 ABCAM LIMITED.
27.14.1 COMPANY OVERVIEW
27.14.2 REVENUE ANALYSIS
27.14.3 GEOGRAPHIC PRESENCE
27.14.4 PRODUCT PORTFOLIO
27.14.5 RECENT DEVELOPMENTS
27.15 ADVACARE PHARMA
27.15.1 COMPANY OVERVIEW
27.15.2 REVENUE ANALYSIS
27.15.3 GEOGRAPHIC PRESENCE
27.15.4 PRODUCT PORTFOLIO
27.15.5 RECENT DEVELOPMENTS
27.16 GETEIN BIOTECH, INC.
27.16.1 COMPANY OVERVIEW
27.16.2 REVENUE ANALYSIS
27.16.3 GEOGRAPHIC PRESENCE
27.16.4 PRODUCT PORTFOLIO
27.16.5 RECENT DEVELOPMENTS
27.17 ATLAS LINK TECHNOLOGY CO. LTD.
27.17.1 COMPANY OVERVIEW
27.17.2 REVENUE ANALYSIS
27.17.3 GEOGRAPHIC PRESENCE
27.17.4 PRODUCT PORTFOLIO
27.17.5 RECENT DEVELOPMENTS
27.18 COSMIC SCIENTIFIC TECHNOLOGIES
27.18.1 COMPANY OVERVIEW
27.18.2 REVENUE ANALYSIS
27.18.3 GEOGRAPHIC PRESENCE
27.18.4 PRODUCT PORTFOLIO
27.18.5 RECENT DEVELOPMENTS
27.19 BIOPANDA REAGENTS LTD,
27.19.1 COMPANY OVERVIEW
27.19.2 REVENUE ANALYSIS
27.19.3 GEOGRAPHIC PRESENCE
27.19.4 PRODUCT PORTFOLIO
27.19.5 RECENT DEVELOPMENTS
27.2 RAYBIOTECH, INC.
27.20.1 COMPANY OVERVIEW
27.20.2 REVENUE ANALYSIS
27.20.3 GEOGRAPHIC PRESENCE
27.20.4 PRODUCT PORTFOLIO
27.20.5 RECENT DEVELOPMENTS
27.21 PROSPEC-TANY TECHNOGENE LTD.
27.21.1 COMPANY OVERVIEW
27.21.2 REVENUE ANALYSIS
27.21.3 GEOGRAPHIC PRESENCE
27.21.4 PRODUCT PORTFOLIO
27.21.5 RECENT DEVELOPMENTS
27.22 BTNX INC.
27.22.1 COMPANY OVERVIEW
27.22.2 REVENUE ANALYSIS
27.22.3 GEOGRAPHIC PRESENCE
27.22.4 PRODUCT PORTFOLIO
27.22.5 RECENT DEVELOPMENTS
27.23 WONDFO
27.23.1 COMPANY OVERVIEW
27.23.2 REVENUE ANALYSIS
27.23.3 GEOGRAPHIC PRESENCE
27.23.4 PRODUCT PORTFOLIO
27.23.5 RECENT DEVELOPMENTS
27.24 ELABSCIENCE BIONOVATION INC.
27.24.1 COMPANY OVERVIEW
27.24.2 REVENUE ANALYSIS
27.24.3 GEOGRAPHIC PRESENCE
27.24.4 PRODUCT PORTFOLIO
27.24.5 RECENT DEVELOPMENTS
27.25 CTK BIOTECH, INC.
27.25.1 COMPANY OVERVIEW
27.25.2 REVENUE ANALYSIS
27.25.3 GEOGRAPHIC PRESENCE
27.25.4 PRODUCT PORTFOLIO
27.25.5 RECENT DEVELOPMENTS
27.26 HIPRO BIOTECHNOLOGY CO.,LTD.
27.26.1 COMPANY OVERVIEW
27.26.2 REVENUE ANALYSIS
27.26.3 GEOGRAPHIC PRESENCE
27.26.4 PRODUCT PORTFOLIO
27.26.5 RECENT DEVELOPMENTS
27.27 QUADRATECH DIAGNOSTICS LTD
27.27.1 COMPANY OVERVIEW
27.27.2 REVENUE ANALYSIS
27.27.3 GEOGRAPHIC PRESENCE
27.27.4 PRODUCT PORTFOLIO
27.27.5 RECENT DEVELOPMENTS
27.28 XIAMEN BIOTIME BIOTECHNOLOGY CO., LTD..
27.28.1 COMPANY OVERVIEW
27.28.2 REVENUE ANALYSIS
27.28.3 GEOGRAPHIC PRESENCE
27.28.4 PRODUCT PORTFOLIO
27.28.5 RECENT DEVELOPMENTS
27.29 TULIP DIAGNOSTIC (P) LTD.
27.29.1 COMPANY OVERVIEW
27.29.2 REVENUE ANALYSIS
27.29.3 GEOGRAPHIC PRESENCE
27.29.4 PRODUCT PORTFOLIO
27.29.5 RECENT DEVELOPMENTS
NOTE: THE COMPANIES PROFILED IS NOT EXHAUSTIVE LIST AND IS AS PER OUR PREVIOUS CLIENT REQUIREMENT. WE PROFILE MORE THAN 100 COMPANIES IN OUR STUDY AND HENCE THE LIST OF COMPANIES CAN BE MODIFIED OR REPLACED ON REQUEST
28 RELATED REPORTS
29 CONCLUSION
30 QUESTIONNAIRE
31 ABOUT DATA BRIDGE MARKET RESEARCH
